<DOC>
	<DOC>NCT02718716</DOC>
	<brief_summary>The primary objective of the study is to check if an subcutaneous (sc) infusion of UCB7665 is safe and tolerated in subjects with primary immune thrombocytopenia.</brief_summary>
	<brief_title>Study to Evaluate Safety, Tolerability and Efficacy of UCB7665 in Subjects With Primary Immune Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
	<criteria>Subject has a diagnosis of primary immune thrombocytopenia (ITP) for a minimum of 3 months prior to Screening Visit Subject has a platelet count &lt;30x10^9/L at Screening and &lt;35x10^9/L at Baseline (Visit 2) Subject has a current or history of a peripheral blood smear consistent with ITP Subject has responded to previous ITP therapy (according to the judgment of the investigator) Subject has an immunoglobulin G (IgG) level ≤6g/L at Screening Visit Subject has a partial thromboplastin time (PTT) ≥1.5x upper limit of normal (ULN) or International Normalized Ratio (INR) ≥1.5 at Screening Visit Subject has renal and/or liver impairment defined as: Serum creatinine level of ≥1.4 mg/dL for females and ≥1.5 mg/dL for males at Screening Visit Subject has planned an elective surgical procedure in the coming 6 months Subject has evidence of a secondary cause of primary immune thrombocytopenia Subject has a history of clinically relevant ongoing chronic infections Subject has a family history of primary immunodeficiency Subject has a clinically relevant active infection or has had a serious infection within 6 weeks prior to the first dose of IMP Subject has a history of known inflammatory bowel disease, diverticular disease, and gastric or esophageal ulceration Subject has experienced gastrointestinal bleed in the last 6 months prior to Screening Visit and/or has current gastritis or esophagitis Subject has a medical history of thrombosis Subject has a history of coagulopathy disorders Subject has received a live vaccination within 8 weeks prior to the Baseline Visit; or intends to have a live vaccination during the course of the study or within 7 weeks following the final dose of IMP Subject has had prior treatment with rituximab in the 6 months prior to the Baseline Subject has not completed the washout period for the immune suppressants, biologics and other therapies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ITP</keyword>
</DOC>